ENTX Insider Trading
Insider Ownership Percentage: 10.90%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00
Entera Bio Share Price & Price History
Current Price: $2.24
Price Change: ▼ Price Decrease of -0.07 (-3.03%)
As of 02/19/2025 05:00 PM ET
Entera Bio Insider Trading History
Entera Bio Institutional Trading History
Data available starting January 2016
Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and OXM for the treatment of obesity and metabolic diseases. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.
Read More on Entera Bio
Volume
49,452 shs
Average Volume
178,298 shs
Market Capitalization
$80.15 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.52
Who are the company insiders with the largest holdings of Entera Bio?
Who are the major institutional investors of Entera Bio?
Entera Bio's top institutional investors include:
- Knoll Capital Management LLC — 16.44%
- Schonfeld Strategic Advisors LLC — 1.77%
- Northern Trust Corp — 0.59%
- Perigon Wealth Management LLC — 0.41%
- Citadel Advisors LLC — 0.00%
- Concourse Financial Group Securities Inc. — 0.00%
Learn More about top institutional investors of Entera Bio stock.
Which major investors are selling Entera Bio stock?
Within the last quarter, ENTX stock was sold by these institutional investors:
- Schonfeld Strategic Advisors LLC
- Citadel Advisors LLC
Which major investors are buying Entera Bio stock?
During the last quarter, ENTX stock was bought by institutional investors including:
- Knoll Capital Management LLC
- Northern Trust Corp
- Perigon Wealth Management LLC
In the last year, these company insiders have bought Entera Bio stock:
- Miranda Jayne Toledano (CEO)
- Sean Ellis (Director)
- Haya Taitel (Director)
Learn More investors buying Entera Bio stock.